The One Penny Stock this Billionaire Is Buying Up

Steve Cohen, the legendary billionaire stock picker known for delivering huge returns for his clients at SAC Capital – one of the most successful hedge funds ever – is at it again.

But this time, he's doing it with his new company Point72 Asset Management – which manages $17.2 billion for high-net-worth individuals.

Even if us normal folks can’t invest in the Point72 fund itself, we can still copy Cohen’s trades…

You see, Point72 is required to disclose all its holding publicly every quarter.

And last quarter, Cohen’s firm revealed a new position in one penny stock that caught my eye.

Here it is…

Cocrystal Pharma Inc. (NASDAQ: COCP)

Cocrystal Pharma is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.

finviz dynamic chart for  COCP

The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs.

COCP is currently developing an oral broad-spectrum replication inhibitor called a non-nucleoside inhibitor – which is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of an ultra-short therapy of four to six weeks.

The stock shot up from $0.87 to $2.16 after Cohen announced his stake in the company late last year.

But now that’s it’s down to only $1.40 per share, that makes Cocrystal Pharma one of the more interesting penny stocks to watch for potentially huge gains in 2021.

If those Phase 2 trials turn out successful and the company moves on to Phase 3, the stock should get a boost. And if Phase 3 is successful, the stock could soar.

The Guardian: “New pill could spell the end of aging.”

Sponsored

Take a look at this picture:

This pill is set to completely change the lives of millions of Americans…

And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…

Investors who get in on the ground floor stand to become rich beyond their wildest dreams.

Here are all the details.